InvestorsHub Logo
Followers 7
Posts 1577
Boards Moderated 0
Alias Born 02/27/2014

Re: schwarzenathan post# 72918

Saturday, 02/07/2015 2:19:33 AM

Saturday, February 07, 2015 2:19:33 AM

Post# of 80869
Paulo Santos, Codie, Bellator_Exec, myself included.....what we think doesn't change anything.

Musclepharm numbers were not too encouraging for q3, but Musclepharm did buy it's stock back at $10 in the beginning of q4 though....that is worth to remember. Also, more than halfway into q4, Musclepharm didn't promise too much bottom line in q4, but believed in it's revenue.

Actually, Musclepharm was so satisfied with revenue that it didn't even bother to promote it's products aggressively during the holidays.
That shows that Musclepharm does care about margins and that Musclepharm does try not to lose too much money.

I think this was the beginning to a shift where Musclepharm tries to incentivize employees to improve capital return and maximize profits over revenue growth at any cost.

Musclepharm is getting more conservative, and it is striving to grow revenues towards critical mass levels in q1 or q2 with the aim to become profitable, and not just to impress investors with higher revenue numbers.